All Stories

  1. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects

    Article • International Journal of Clinical Pharmacology and Therapeutics, March 2015, Dustri-Verlgag Dr. Karl Feistle

    Dr Masaki Hiraoka

  2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects

    Article • International Journal of Clinical Pharmacology and Therapeutics, April 2014, Dustri-Verlgag Dr. Karl Feistle

    Dr Masaki Hiraoka

  3. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?

    Article • The Journal of Clinical Pharmacology, January 2014, Wiley

    Dr Masaki Hiraoka

  4. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study

    Article • Modern Rheumatology, July 2013, Taylor & Francis

    Dr Masaki Hiraoka

  5. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study

    Article • Modern Rheumatology, July 2012, Taylor & Francis

    Dr Masaki Hiraoka

  6. Markov Chain Monte Carlo Bayesian Analysis for Population Pharmacokinetics of Dasatinib in Japanese Adult Subjects with Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    Article • Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, January 2012, Japanese Society of Clinical Pharmacology and Therapeutics

    Dr Masaki Hiraoka

  7. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

    Article • Journal of Pharmacokinetics and Pharmacodynamics, October 2011, Springer Science + Business Media

    Dr Masaki Hiraoka

  8. Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients

    Article • Diagnostic Microbiology and Infectious Disease, May 2011, Elsevier

    Dr Masaki Hiraoka

  9. The safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-708163 in young and elderly Japanese subjects

    Article • Alzheimer s & Dementia, July 2010, Elsevier

    Dr Masaki Hiraoka

  10. Clinical Pharmacology of Antimicrobial Agents: 6.Clinical Studies of Antimicrobial Agents: Use of PK/PD Information

    Article • Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, January 2005, Japanese Society of Clinical Pharmacology and Therapeutics

    Dr Masaki Hiraoka

  11. Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor

    Article • Cancer Chemotherapy and Pharmacology, January 1996, Springer Science + Business Media

    Dr Masaki Hiraoka

  12. Enantioselective determination of sotalol enantiomers in biological fluids using high-performance liquid chromatography

    Article • Journal of Chromatography B Biomedical Sciences and Applications, December 1995, Elsevier

    Dr Masaki Hiraoka

  13. Pharmacokinetics of Sotalol Enantiomers after Single and Repeated Oral Administration of Sotalol Hydrochloride to Rats.

    Article • January 1995, Japanese Society for the Study of Xenobiotics

    Dr Masaki Hiraoka

  14. Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester.

    Article • Antimicrobial Agents and Chemotherapy, April 1990, ASM Journals

    Dr Masaki Hiraoka

  15. Effects of beta-lactamases and omp mutation on susceptibility to beta-lactam antibiotics in Escherichia coli.

    Article • Antimicrobial Agents and Chemotherapy, March 1989, ASM Journals

    Dr Masaki Hiraoka

  16. Interaction of cefpirome and a cephalosporinase from Citrobacter freundii GN7391.

    Article • Antimicrobial Agents and Chemotherapy, March 1989, ASM Journals

    Dr Masaki Hiraoka

  17. Hydrolytic Rate at Low Drug Concentration as a Limiting Factor in Resistance to Newer Cephalosporins

    Article • Clinical Infectious Diseases, July 1988, Oxford University Press (OUP)

    Dr Masaki Hiraoka

  18. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxime.

    Article • The Journal of Antibiotics, January 1988, Japan Antibiotics Research Association

    Dr Masaki Hiraoka

  19. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100

    Article • European Journal of Clinical Microbiology & Infectious Diseases, October 1987, Springer Science + Business Media

    Dr Masaki Hiraoka

  20. MUTAGENICITY TESTS OF ETOPOSIDE AND TENIPOSIDE

    Article • The Journal of Toxicological Sciences, January 1986, Japanese Society of Toxicology

    Dr Masaki Hiraoka